Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).

Schenk JM, Neuhouser ML, Beatty SJ, VanDoren M, Lin DW, Porter M, Gore JL, Gulati R, Plymate SR, Wright JL.

Contemp Clin Trials. 2019 Jun;81:34-39. doi: 10.1016/j.cct.2019.04.004. Epub 2019 Apr 16.

PMID:
31002955
2.

The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.

Watts EL, Perez-Cornago A, Appleby PN, Albanes D, Ardanaz E, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chubb SAP, Cook MB, Deschasaux M, Donovan JL, English DR, Flicker L, Freedman ND, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Häggström C, Haiman C, Hamdy FC, Hercberg S, Holly JM, Huang J, Huang WY, Johansson M, Kaaks R, Kubo T, Lane JA, Layne TM, Le Marchand L, Martin RM, Metter EJ, Mikami K, Milne RL, Morris HA, Mucci LA, Neal DE, Neuhouser ML, Oliver SE, Overvad K, Ozasa K, Pala V, Pernar CH, Pollak M, Rowlands MA, Schaefer CA, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Touvier M, Trichopoulou A, Tsilidis KK, Van Den Eeden SK, Weinstein SJ, Wilkens L, Yeap BB, Key TJ, Allen NE, Travis RC.

Int J Cancer. 2019 Mar 15. doi: 10.1002/ijc.32276. [Epub ahead of print]

PMID:
30873591
3.

A Novel Mobile Structured Light System in Food 3D Reconstruction and Volume Estimation.

Makhsous S, Mohammad HM, Schenk JM, Mamishev AV, Kristal AR.

Sensors (Basel). 2019 Jan 29;19(3). pii: E564. doi: 10.3390/s19030564.

4.

A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.

Travis RC, Perez-Cornago A, Appleby PN, Albanes D, Joshu CE, Lutsey PL, Mondul AM, Platz EA, Weinstein SJ, Layne TM, Helzlsouer KJ, Visvanathan K, Palli D, Peeters PH, Bueno-de-Mesquita B, Trichopoulou A, Gunter MJ, Tsilidis KK, Sánchez MJ, Olsen A, Brenner H, Schöttker B, Perna L, Holleczek B, Knekt P, Rissanen H, Yeap BB, Flicker L, Almeida OP, Wong YYE, Chan JM, Giovannucci EL, Stampfer MJ, Ursin G, Gislefoss RE, Bjørge T, Meyer HE, Blomhoff R, Tsugane S, Sawada N, English DR, Eyles DW, Heath AK, Williamson EJ, Manjer J, Malm J, Almquist M, Marchand LL, Haiman CA, Wilkens LR, Schenk JM, Tangen CM, Black A, Cook MB, Huang WY, Ziegler RG, Martin RM, Hamdy FC, Donovan JL, Neal DE, Touvier M, Hercberg S, Galan P, Deschasaux M, Key TJ, Allen NE.

Cancer Res. 2019 Jan 1;79(1):274-285. doi: 10.1158/0008-5472.CAN-18-2318. Epub 2018 Nov 13.

5.

Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.

Kearns JT, Faino AV, Schenk JM, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner A, Zheng Y, Lin DW.

J Urol. 2019 Jan;201(1):106-111. doi: 10.1016/j.juro.2018.07.065.

PMID:
30076904
6.

Comparison of Nutrient Estimates Based on Food Volume versus Weight: Implications for Dietary Assessment Methods.

Partridge EK, Neuhouser ML, Breymeyer K, Schenk JM.

Nutrients. 2018 Jul 27;10(8). pii: E973. doi: 10.3390/nu10080973.

7.

Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda.

Coghill AE, Schenk JM, Mahkoul Z, Orem J, Phipps W, Casper C.

AIDS. 2018 Feb 20;32(4):505-512. doi: 10.1097/QAD.0000000000001722.

8.

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.

Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA, Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA, Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E, Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ, Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM, Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC.

PLoS One. 2017 Dec 27;12(12):e0187741. doi: 10.1371/journal.pone.0187741. eCollection 2017.

9.

Plasma Fatty Acids as Surrogate for Prostate Levels.

Schenk JM, Song X, Morrissey C, Vessella RL, Lin DW, Neuhouser ML.

Nutr Cancer. 2018 Jan;70(1):45-50. doi: 10.1080/01635581.2018.1412479. Epub 2017 Dec 21.

10.

Inter-Rater Reliability of Provider Interpretations of Irritable Bowel Syndrome Food and Symptom Journals.

Zia J, Chung CF, Xu K, Dong Y, Schenk JM, Cain K, Munson S, Heitkemper MM.

J Clin Med. 2017 Nov 4;6(11). pii: E105. doi: 10.3390/jcm6110105.

11.

A Pooled Analysis of 15 Prospective Cohort Studies on the Association between Fruit, Vegetable, and Mature Bean Consumption and Risk of Prostate Cancer.

Petimar J, Wilson KM, Wu K, Wang M, Albanes D, van den Brandt PA, Cook MB, Giles GG, Giovannucci EL, Goodman GE, Goodman PJ, Håkansson N, Helzlsouer K, Key TJ, Kolonel LN, Liao LM, Männistö S, McCullough ML, Milne RL, Neuhouser ML, Park Y, Platz EA, Riboli E, Sawada N, Schenk JM, Tsugane S, Verhage B, Wang Y, Wilkens LR, Wolk A, Ziegler RG, Smith-Warner SA.

Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1276-1287. doi: 10.1158/1055-9965.EPI-16-1006. Epub 2017 Apr 26.

12.

Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.

Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML.

Nutrients. 2017 Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378.

13.

Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.

Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM Jr.

J Clin Oncol. 2016 Dec 20;34(36):4338-4344. Epub 2016 Oct 28. Review.

14.

Changes in relative and absolute concentrations of plasma phospholipid fatty acids observed in a randomized trial of Omega-3 fatty acids supplementation in Uganda.

Song X, Diep P, Schenk JM, Casper C, Orem J, Makhoul Z, Lampe JW, Neuhouser ML.

Prostaglandins Leukot Essent Fatty Acids. 2016 Nov;114:11-16. doi: 10.1016/j.plefa.2016.09.002. Epub 2016 Sep 30.

15.

Measurement of Circulating Phospholipid Fatty Acids: Association between Relative Weight Percentage and Absolute Concentrations.

Song X, Schenk JM, Diep P, Murphy RA, Harris TB, Eiriksdottir G, Gudnason V, Casper C, Lampe JW, Neuhouser ML.

J Am Coll Nutr. 2016 Sep-Oct;35(7):647-656. Epub 2016 Jun 17.

16.

The feasibility, usability, and clinical utility of traditional paper food and symptom journals for patients with irritable bowel syndrome.

Zia JK, Chung CF, Schroeder J, Munson SA, Kientz JA, Fogarty J, Bales E, Schenk JM, Heitkemper MM.

Neurogastroenterol Motil. 2017 Feb;29(2). doi: 10.1111/nmo.12935. Epub 2016 Sep 12.

PMID:
27619957
17.

A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Liss MA, Schenk JM, Faino AV, Newcomb LF, Boyer H, Brooks JD, Carroll PR, Dash A, Fabrizio MD, Gleave ME, Nelson PS, Neuhouser ML, Wei JT, Zheng Y, Wright JL, Lin DW, Thompson IM.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):390-394. doi: 10.1038/pcan.2016.28. Epub 2016 Jul 19.

18.

Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.

Allen NE, Travis RC, Appleby PN, Albanes D, Barnett MJ, Black A, Bueno-de-Mesquita HB, Deschasaux M, Galan P, Goodman GE, Goodman PJ, Gunter MJ, Heliövaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Knekt P, Kolonel LN, Lasheras C, Linseisen J, Metter EJ, Neuhouser ML, Olsen A, Pala V, Platz EA, Rissanen H, Reid ME, Schenk JM, Stampfer MJ, Stattin P, Tangen CM, Touvier M, Trichopoulou A, van den Brandt PA, Key TJ; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.

J Natl Cancer Inst. 2016 Jul 6;108(11). doi: 10.1093/jnci/djw153. Print 2016 Nov.

19.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

20.

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, Bueno-de-Mesquita HBA, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JAMJL, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak M, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE.

Cancer Res. 2016 Apr 15;76(8):2288-2300. doi: 10.1158/0008-5472.CAN-15-1551. Epub 2016 Feb 26.

21.

Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies.

Wu K, Spiegelman D, Hou T, Albanes D, Allen NE, Berndt SI, van den Brandt PA, Giles GG, Giovannucci E, Alexandra Goldbohm R, Goodman GG, Goodman PJ, Håkansson N, Inoue M, Key TJ, Kolonel LN, Männistö S, McCullough ML, Neuhouser ML, Park Y, Platz EA, Schenk JM, Sinha R, Stampfer MJ, Stevens VL, Tsugane S, Visvanathan K, Wilkens LR, Wolk A, Ziegler RG, Smith-Warner SA.

Int J Cancer. 2016 May 15;138(10):2368-82. doi: 10.1002/ijc.29973.

22.

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM.

Cancer Causes Control. 2016 Feb;27(2):175-82. doi: 10.1007/s10552-015-0695-0. Epub 2015 Nov 20.

23.

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Key TJ, Appleby PN, Travis RC, Albanes D, Alberg AJ, Barricarte A, Black A, Boeing H, Bueno-de-Mesquita HB, Chan JM, Chen C, Cook MB, Donovan JL, Galan P, Gilbert R, Giles GG, Giovannucci E, Goodman GE, Goodman PJ, Gunter MJ, Hamdy FC, Heliövaara M, Helzlsouer KJ, Henderson BE, Hercberg S, Hoffman-Bolton J, Hoover RN, Johansson M, Khaw KT, King IB, Knekt P, Kolonel LN, Le Marchand L, Männistö S, Martin RM, Meyer HE, Mondul AM, Moy KA, Neal DE, Neuhouser ML, Palli D, Platz EA, Pouchieu C, Rissanen H, Schenk JM, Severi G, Stampfer MJ, Tjønneland A, Touvier M, Trichopoulou A, Weinstein SJ, Ziegler RG, Zhou CK, Allen NE; Endogenous Hormones Nutritional Biomarkers Prostate Cancer Collaborative Group.

Am J Clin Nutr. 2015 Nov;102(5):1142-57. doi: 10.3945/ajcn.115.114306. Epub 2015 Oct 7.

24.

Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial.

Patel DP, Schenk JM, Darke A, Myers JB, Brant WO, Hotaling JM.

BJU Int. 2016 Mar;117(3):500-6. doi: 10.1111/bju.13264. Epub 2015 Sep 20.

25.

Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM Jr, Lucia MS, Kristal AR.

JAMA Oncol. 2015 Jun;1(3):342-9. doi: 10.1001/jamaoncol.2015.0513. Erratum in: JAMA Oncol. 2015 Jun;1(3):322.

26.

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD.

PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015.

27.

Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA.

Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.

28.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1484-93. doi: 10.1158/1055-9965.EPI-13-1340.

29.

Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial.

Kristal AR, Till C, Song X, Tangen CM, Goodman PJ, Neuhauser ML, Schenk JM, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1494-504. doi: 10.1158/1055-9965.EPI-14-0115. Epub 2014 Apr 14.

30.

Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia?

Schenk JM, Hunter-Merrill R, Zheng Y, Etzioni R, Gulati R, Tangen C, Thompson IM, Kristal AR.

Am J Epidemiol. 2013 Sep 1;178(5):741-51. doi: 10.1093/aje/kwt044. Epub 2013 Jun 28.

31.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR.

Am J Epidemiol. 2012 Jul 15;176(2):156-63. doi: 10.1093/aje/kwr524. Epub 2012 Jun 28.

32.

Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.

Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, Kristal AR; Prostate Cancer Prevention Trial; Urologic Diseases in America Project.

Eur Urol. 2012 Aug;62(2):234-41. doi: 10.1016/j.eururo.2012.03.007. Epub 2012 Mar 14.

33.

Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.

Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.

Am J Epidemiol. 2011 Jun 15;173(12):1419-28. doi: 10.1093/aje/kwq493. Epub 2011 May 3. Erratum in: Am J Epidemiol. 2011 Dec 15;174(12):1425.

34.

Brief telephone intervention increases soy intake in peri- and postmenopausal US women: the Herbal Alternatives Trial (HALT).

Beasley JM, Schenk JM, Ludman E, Lampe JW, Reed SD, Grothaus L, Newton KM.

J Am Diet Assoc. 2010 Aug;110(8):1189-97. doi: 10.1016/j.jada.2010.05.001.

35.

Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM.

Am J Epidemiol. 2010 Mar 1;171(5):571-82. doi: 10.1093/aje/kwp406. Epub 2010 Feb 8.

36.

Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Kristal AR, Price DK, Till C, Schenk JM, Neuhouser ML, Ockers S, Lin DW, Thompson IM, Figg WD.

Prostate. 2010 May 1;70(6):584-90. doi: 10.1002/pros.21092.

37.

Development and validation of the mindful eating questionnaire.

Framson C, Kristal AR, Schenk JM, Littman AJ, Zeliadt S, Benitez D.

J Am Diet Assoc. 2009 Aug;109(8):1439-44. doi: 10.1016/j.jada.2009.05.006.

38.

Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM.

Cancer. 2009 Aug 15;115(16):3661-9. doi: 10.1002/cncr.24423.

39.

Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM.

Prostate. 2009 Sep 1;69(12):1303-11. doi: 10.1002/pros.20974.

40.

Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.

Schenk JM, Riboli E, Chatterjee N, Leitzmann MF, Ahn J, Albanes D, Reding DJ, Wang Y, Friesen MD, Hayes RB, Peters U.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1227-31. doi: 10.1158/1055-9965.EPI-08-0984. Epub 2009 Mar 31.

41.
42.

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.

Am J Epidemiol. 2008 Dec 15;168(12):1416-24. doi: 10.1093/aje/kwn272. Epub 2008 Oct 21.

43.

Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.

Dong LM, Kristal AR, Peters U, Schenk JM, Sanchez CA, Rabinovitch PS, Blount PL, Odze RD, Ayub K, Reid BJ, Vaughan TL.

Nutr Cancer. 2008;60(1):39-48. doi: 10.1080/01635580701586762.

44.

Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM.

Am J Epidemiol. 2008 Apr 15;167(8):925-34. doi: 10.1093/aje/kwm389. Epub 2008 Feb 7.

PMID:
18263602
45.

Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues.

Lin DW, Neuhouser ML, Schenk JM, Coleman IM, Hawley S, Gifford D, Hung H, Knudsen BS, Nelson PS, Kristal AR.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2150-4.

46.

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, Penson DF, Thompson IM.

J Urol. 2007 Apr;177(4):1395-400; quiz 1591.

PMID:
17382740
47.

Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus.

Kristal AR, Blount PL, Schenk JM, Sanchez CA, Rabinovitch PS, Odze RD, Standley J, Vaughan TL, Reid BJ.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2377-83.

48.

Directions for future epidemiological research in lycopene and prostate cancer risk.

Kristal AR, Schenk JM.

J Nutr. 2005 Aug;135(8):2037S-9S. Review. No abstract available.

PMID:
16046734

Supplemental Content

Loading ...
Support Center